AMAG Pharmaceuticals, Inc. (AMAG)
-NasdaqGS 20.21 
0.30(1.46%) Jun 17, 4:00PM EDT
| Prev Close: | 20.51 |
|---|
| Open: | 20.50 |
|---|
| Bid: | N/A |
|---|
| Ask: | 24.25 x 200 |
|---|
| 1y Target Est: | 21.86 |
|---|
| Beta: | 0.18 |
|---|
| Next Earnings Date: | 22-Jul-13 |
|---|
| Day's Range: | 19.95 - 20.74 |
|---|
| 52wk Range: | 13.85 - 25.67 |
|---|
| Volume: | 106,167 |
|---|
| Avg Vol (3m): | 141,561 |
|---|
| Market Cap: | 436.01M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.38 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- AMAG PHARMACEUTICALS INC. Files SEC form 8-K, Creation of a Direct Financial Obligation or an Obligation under an OffEDGAR Online(Thu, Jun 13)
- Label Expansion Sought for AMAG/TKPYY's RiensoZacks(Mon, Jun 10)
- AMAG Pharmaceuticals Obtains US Commercial Rights to MuGard(TM) A Prescription Oral Rinse to Manage Oral MucositisGlobeNewswire(Mon, Jun 10)
- Access Pharmaceuticals Signs US License Agreement With AMAG Pharmaceuticals For MuGardPR Newswire(Mon, Jun 10)
- AMAG PHARMACEUTICALS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and ExEDGAR Online(Mon, Jun 10)
- AMAG Pharmaceuticals Announces Submission of a Type II Variation for Rienso Label Expansion in Europe to Include All Adult Iron Deficiency Anemia Patients Who Cannot Take Oral IronGlobeNewswire(Fri, Jun 7)
- Solid Showing At WCN Conference For Keryx: Catalysts Still To Comeat Seeking Alpha(Tue, Jun 4)
- AMAG Pharmaceuticals, Inc. to Present at Upcoming Investor ConferencesGlobeNewswire(Mon, Jun 3)
- Keryx: Attractive In Front Of Catalyst-Rich Second Halfat Seeking Alpha(Thu, May 30)
- SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on Their Investment in AMAG Pharmaceuticals, Inc. of Class Action Lawsuit Investigation - AMAGPR Newswire(Tue, May 28)
- 3 Horrendous Health-Care Stocks This Weekat Motley Fool(Sat, May 25)
- AMAG PHARMACEUTICALS INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a VEDGAR Online(Fri, May 24)
- A Review Of Upcoming Catalysts For Kidney Disease Biotech Players In 2013at Seeking Alpha(Fri, May 24)
- The Zacks Analyst Blog Highlights: AMAG Pharmaceuticals, Takeda Pharmaceutical, DISH Network, Sprint Nextel and Verizon CommunicationsZacks(Thu, May 23)
- Bronstein, Gewirtz & Grossman, LLC Announces Investigation of AMAG Pharmaceuticals, Inc.PR Newswire(Wed, May 22)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 5.04 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.67 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.17 |
|---|
| Mean Recommendation*: | 2.4 |
|---|
| PEG Ratio (5 yr expected): | -0.44 |
|---|
Business Summary
AMAG Pharmaceuticals, Inc., a biopharmaceutical company, engages the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia (IDA).
View More